 Anip Bansal
Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 4 | 2014 | 600 | 0.840 |
Why?
| | Acute Kidney Injury | 8 | 2026 | 873 | 0.820 |
Why?
| | Renal Dialysis | 4 | 2014 | 465 | 0.730 |
Why?
| | Metabolic Syndrome | 1 | 2025 | 355 | 0.680 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 663 | 0.680 |
Why?
| | Kidney Diseases | 1 | 2025 | 427 | 0.660 |
Why?
| | Ferritins | 2 | 2014 | 70 | 0.520 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2014 | 14 | 0.420 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 62 | 0.400 |
Why?
| | Renal Replacement Therapy | 2 | 2026 | 100 | 0.380 |
Why?
| | Cisplatin | 2 | 2025 | 345 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 1 | 2012 | 58 | 0.360 |
Why?
| | Iron | 1 | 2014 | 359 | 0.350 |
Why?
| | Obesity | 1 | 2025 | 3076 | 0.340 |
Why?
| | Hospital Mortality | 5 | 2021 | 1044 | 0.310 |
Why?
| | Tumor Lysis Syndrome | 1 | 2026 | 9 | 0.250 |
Why?
| | Urate Oxidase | 1 | 2026 | 13 | 0.240 |
Why?
| | Gout Suppressants | 1 | 2026 | 20 | 0.240 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1216 | 0.240 |
Why?
| | Calcium | 1 | 2012 | 1190 | 0.240 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2025 | 3 | 0.230 |
Why?
| | Magnesium | 1 | 2025 | 156 | 0.220 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2025 | 105 | 0.210 |
Why?
| | Methotrexate | 1 | 2025 | 232 | 0.200 |
Why?
| | Intensive Care Units | 5 | 2021 | 925 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2023 | 7 | 0.190 |
Why?
| | Terminology as Topic | 1 | 2025 | 255 | 0.190 |
Why?
| | Hyponatremia | 1 | 2023 | 43 | 0.190 |
Why?
| | Diabetic Nephropathies | 1 | 2025 | 318 | 0.170 |
Why?
| | Running | 1 | 2023 | 230 | 0.160 |
Why?
| | Middle Aged | 14 | 2026 | 36176 | 0.150 |
Why?
| | Administration, Intravenous | 2 | 2025 | 171 | 0.150 |
Why?
| | Critical Illness | 3 | 2021 | 901 | 0.150 |
Why?
| | Dialysis Solutions | 1 | 2019 | 23 | 0.150 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 76 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Risk Factors | 4 | 2025 | 10874 | 0.130 |
Why?
| | Disease Progression | 1 | 2025 | 2862 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1498 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 325 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2025 | 1244 | 0.120 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 389 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 409 | 0.120 |
Why?
| | Humans | 20 | 2026 | 145491 | 0.120 |
Why?
| | Aged | 9 | 2026 | 26125 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 520 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
| | Pyrazoles | 1 | 2019 | 517 | 0.110 |
Why?
| | Pericardiocentesis | 1 | 2014 | 10 | 0.110 |
Why?
| | Colchicine | 1 | 2014 | 21 | 0.110 |
Why?
| | Oliguria | 1 | 2014 | 2 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 994 | 0.110 |
Why?
| | Hematinics | 1 | 2014 | 22 | 0.110 |
Why?
| | Critical Care | 1 | 2020 | 703 | 0.100 |
Why?
| | Pericardial Effusion | 1 | 2014 | 22 | 0.100 |
Why?
| | Intra-Abdominal Hypertension | 1 | 2014 | 7 | 0.100 |
Why?
| | Cohort Studies | 5 | 2024 | 5992 | 0.100 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 103 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2207 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 127 | 0.100 |
Why?
| | Hemodialysis Solutions | 1 | 2012 | 3 | 0.100 |
Why?
| | Adult | 10 | 2026 | 40707 | 0.090 |
Why?
| | Bacterial Infections | 1 | 2014 | 247 | 0.090 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 114 | 0.090 |
Why?
| | Glomerulonephritis | 1 | 2012 | 46 | 0.090 |
Why?
| | Female | 11 | 2026 | 78763 | 0.090 |
Why?
| | Male | 12 | 2026 | 72817 | 0.080 |
Why?
| | Complement C3 | 1 | 2012 | 192 | 0.080 |
Why?
| | Up-Regulation | 1 | 2014 | 848 | 0.080 |
Why?
| | Aluminum | 1 | 2011 | 43 | 0.080 |
Why?
| | Calcinosis | 1 | 2012 | 235 | 0.080 |
Why?
| | Quality Improvement | 1 | 2019 | 1294 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2030 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2897 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2024 | 17269 | 0.070 |
Why?
| | Ambulatory Care | 1 | 2012 | 608 | 0.070 |
Why?
| | Biomarkers | 2 | 2014 | 4283 | 0.060 |
Why?
| | Neutropenia | 1 | 2025 | 155 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2021 | 11831 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8326 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 7171 | 0.050 |
Why?
| | Diuretics | 1 | 2023 | 68 | 0.050 |
Why?
| | Vasopressins | 1 | 2023 | 61 | 0.050 |
Why?
| | Risk Assessment | 2 | 2024 | 3759 | 0.040 |
Why?
| | Creatinine | 1 | 2024 | 513 | 0.040 |
Why?
| | Pandemics | 2 | 2020 | 1706 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1367 | 0.040 |
Why?
| | Prone Position | 1 | 2021 | 24 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2021 | 47 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 55 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2021 | 62 | 0.040 |
Why?
| | Patient Positioning | 1 | 2021 | 69 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2458 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 176 | 0.040 |
Why?
| | United States | 3 | 2020 | 16115 | 0.030 |
Why?
| | Mortality | 1 | 2021 | 379 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 221 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 482 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1332 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 338 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 712 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2093 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2130 | 0.030 |
Why?
| | Anticoagulants | 1 | 2021 | 750 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 14192 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2915 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3340 | 0.020 |
Why?
| | Glomerulonephritis, Membranous | 1 | 2012 | 3 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22485 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1040 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4572 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1507 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2945 | 0.010 |
Why?
|
|
Bansal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|